Status:
UNKNOWN
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Lead Sponsor:
Holy Name Medical Center, Inc.
Collaborating Sponsors:
Biogen
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Some of the most common side effects of the multiple sclerosis drug Plegridy (pegylated interferon beta-1a) include flu-like symptoms and injection site reactions. Physicians often advise patients to ...
Detailed Description
Multiple Sclerosis (MS) is a chronic neurological disease characterized by demyelination of the brain and spine. Currently, there are several treatments designed to decrease the frequency of attacks a...
Eligibility Criteria
Inclusion
- diagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) score
Exclusion
- prior allergic reaction to interferon products, congestive heart failure, elevated liver enzymes
Key Trial Info
Start Date :
September 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03424733
Start Date
September 25 2017
End Date
May 31 2020
Last Update
August 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Holy Name Medical Center
Teaneck, New Jersey, United States, 07666